Tower Research Capital (TRC)’s X4 Pharmaceuticals XFOR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $36.2K | Buy |
7,745
+7,565
| +4,203% | +$31K | ﹤0.01% | 3014 |
|
|
2026
Q1 | $743 | Sell |
180
-10,266
| -98% | -$38.5K | ﹤0.01% | 4790 |
|
|
2025
Q4 | $41.8K | Sell |
10,446
-233
| -2% | -$847 | ﹤0.01% | 2563 |
|
|
2025
Q3 | $36.5K | Buy |
10,679
+5,476
| +105% | +$14.1K | ﹤0.01% | 2768 |
|
|
2025
Q2 | $9.89K | Buy |
5,203
+4,185
| +411% | +$17.1K | ﹤0.01% | 3976 |
|
|
2025
Q1 | $7.22K | Buy |
1,018
+498
| +96% | +$6.86K | ﹤0.01% | 3970 |
|
|
2024
Q4 | $11.4K | Buy |
520
+161
| +45% | +$2.57K | ﹤0.01% | 3714 |
|
|
2024
Q3 | $7.21K | Sell |
359
-540
| -60% | -$11.3K | ﹤0.01% | 4067 |
|
|
2024
Q2 | $15.6K | Buy |
899
+359
| +66% | +$11.7K | ﹤0.01% | 3899 |
|
|
2024
Q1 | $22.5K | Buy |
540
+129
| +31% | +$3.59K | ﹤0.01% | 2892 |
|
|
2023
Q4 | $10.4K | Buy |
411
+68
| +20% | +$1.65K | ﹤0.01% | 4258 |
|
|
2023
Q3 | $11.2K | Buy |
343
+149
| +77% | +$6.5K | ﹤0.01% | 4024 |
|
|
2023
Q2 | $11.3K | Buy |
194
+167
| +619% | +$8.58K | ﹤0.01% | 3994 |
|
|
2023
Q1 | $1K | Sell |
27
-314
| -92% | -$9.21K | ﹤0.01% | 5632 |
|
|
2022
Q4 | $10K | Buy |
+341
| New | +$16.2K | ﹤0.01% | 4095 |
|
|
2022
Q3 | – | Sell |
-188
| Closed | -$5K | – | 6547 |
|
|
2022
Q2 | $5K | Sell |
188
-135
| -42% | -$5.13K | ﹤0.01% | 5116 |
|
|
2022
Q1 | $16K | Buy |
+323
| New | +$18.5K | ﹤0.01% | 3772 |
|
|
2021
Q4 | – | Sell |
-42
| Closed | -$7K | – | 6624 |
|
|
2021
Q3 | $7K | Sell |
42
-399
| -90% | -$65.6K | ﹤0.01% | 4683 |
|
|
2021
Q2 | $86K | Buy |
441
+340
| +337% | +$85.5K | ﹤0.01% | 2550 |
|
|
2021
Q1 | $26K | Sell |
101
-103
| -50% | -$27.1K | ﹤0.01% | 3690 |
|
|
2020
Q4 | $39K | Sell |
204
-382
| -65% | -$75K | ﹤0.01% | 3353 |
|
|
2020
Q3 | $119K | Buy |
586
+483
| +469% | +$116K | ﹤0.01% | 3017 |
|
|
2020
Q2 | $29K | Buy |
+103
| New | +$28.2K | ﹤0.01% | 3469 |
|
|
2019
Q3 | – | Sell |
-66
| Closed | -$30K | – | 4557 |
|
|
2019
Q2 | $30K | Buy |
66
+51
| +340% | +$25.9K | ﹤0.01% | 1918 |
|
|
2019
Q1 | $8K | Buy |
+15
| New | +$8.28K | ﹤0.01% | 2827 |
|
|
2018
Q4 | – | Sell |
-8
| Closed | -$3.05K | – | 4438 |
|
|
2018
Q3 | $2K | Sell |
8
-6
| -43% | -$2.54K | ﹤0.01% | 3492 |
|
|
2018
Q2 | $9K | Buy |
14
+3
| +27% | +$9.82K | ﹤0.01% | 2843 |
|
|
2018
Q1 | $44K | Buy |
+11
| New | +$32K | ﹤0.01% | 1745 |
|
Other funds holding XFOR
BCLSI
PA
SVCM
EAM
DTC
KCM
Tower Research Capital (TRC)'s XFOR Position: Q2 2026 in Review
Tower Research Capital (TRC) increased its X4 Pharmaceuticals (XFOR) stake by 4,203% in Q2 2026, buying an estimated $31K and bringing the position to 7,745 shares worth $36.2K. The position accounts for ﹤0.01% of the portfolio, ranked #3014.
Tower Research Capital (TRC) first reported a position in XFOR in Q1 2018 and has held it in 28 quarters since. The position peaked at $119K in Q3 2020. 89 funds tracked by Wall St. Rank hold XFOR as of Q2 2026.
- Tower Research Capital (TRC) held 7,745 shares of X4 Pharmaceuticals worth $36.2K as of Q2 2026.
- Tower Research Capital (TRC) bought 7,565 X4 Pharmaceuticals shares in Q2 2026, an estimated $31K.
- X4 Pharmaceuticals made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q2 2026, its #3014 holding.
- Tower Research Capital (TRC) first reported a position in X4 Pharmaceuticals in Q1 2018 and has held it in 28 quarters since.
- Tower Research Capital (TRC)'s X4 Pharmaceuticals position peaked at $119K in Q3 2020.
- 89 funds tracked by Wall St. Rank held X4 Pharmaceuticals as of Q2 2026.
Based on Tower Research Capital (TRC)'s 13F filing for Q2 2026, filed 11 Aug 2026.